Anti–β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome

Galli, Mónica; Luciani, Davide; Bertolini, Guido; Barbui, Tiziano

doi:10.1182/blood-2002-11-3334

Cited by 405 publications

(290 citation statements)

References 54 publications

Supporting

Mentioning

260

Contrasting

Unclassified

Order By: Relevance

“…Some experts argue that, as APS patients are unlikely to be negative for both aCL (IgG and IgM) and LA, it is superfluous to test for aβ2GP1 (4) and IgA aCL (5). The role of aPT as markers of thrombophilia in SLE appears to be even more tenuous, and is, at best, only partially supported by the published literature (6)(7)(8).…”

Section: List Of Tablesmentioning

confidence: 91%

Prevalence and clinical correlates of anti‐phospholipid antibodies in South Africans with systemic lupus erythematosus

Gould

Tikly

Asherson

et al. 2006

Scandinavian Journal of Rheumatology

View full text Add to dashboard Cite

were documented, and sera tested for aCL, aβ 2 GP, and aPT of all isotypes, and LA.RESULTS: Positive aCL, aβ 2 GP1 and aPT and LA were found in 53, 84, 20, and 2 patients, respectively. Immunoglobulin (Ig)A aCL and IgG aβ 2 GP1 were the commonest aCL (49.1%) and aβ 2 GP1 (47%) isotypes, respectively. IgA aβ2GP1 were associated with both a history of thrombosis alone (p<0.05) and a history of any clinical feature, thrombosis and/or spontaneous abortion of the APS (p<0.05); IgA aCL were associated with a history of any clinical APS event (p<0.05); and aβ2GPI of any isotype were associated with a history of arthritis (p<0.001).CONCLUSION: My findings provide further evidence that the screening for aβ 2 GP1 and IgA aCL isotype may improve the risk assessment for APS in SLE patients of African extraction.

show abstract

Section: List Of Tablesmentioning

confidence: 91%

Prevalence and clinical correlates of anti‐phospholipid antibodies in South Africans with systemic lupus erythematosus

Gould

Tikly

Asherson

et al. 2006

Scandinavian Journal of Rheumatology

View full text Add to dashboard Cite

show abstract

“…aCL and anti-β2GPI). The differing sensitivity and specificity of the liquid-phase and solid-phase aPL assays for clinical features of APS [37,38] may thus affect the likelihood of APS being diagnosed.…”

Section: Key Laboratory Issues Related To Apl Testingmentioning

confidence: 99%

The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours?

Favaloro

Wong

2010

Autoimmun Highlights

View full text Add to dashboard Cite

show abstract

“…Recent studies have shown that affinitypurified human anti-b2GPI antibodies induce thrombosis in mice (Galli et al, 2003;Arad et al, 2011). Anti-b2GPI antibodies may promote thrombosis through b2GPI-dependent activation of ECs by increasing the expression of adhesion molecules (E-selectin SELE, vascular cell adhesion molecule 1 [VCAM1], intercellular adhesion molecule 1 [ICAM1]) and tissue factor (TF; coagulation factor III, FIII, F3) and enhancing the expression, synthesis, and/or secretion of proinflammatory cytokines (interleukin (IL)-1b [IL1B], I-6, IL8, monocyte chemotactic protein 1 [MCP1; chemokine (C-C motif) ligand 2, CCL2], tumour necrosis factor-a [TNF-a; TNF]) and chemokines, and eventually lead to a pro-inflammatory and procoagulant monocyte phenotype characterized by the release of TNF-a and TF, respectively (Meroni et al, 2001;Conti et al, 2003;Riboldi et al, 2003;Sorice et al, 2007).…”

Section: B2-glycoprotein I (B2gpi) and Its Receptors On The Cell Surfacementioning

confidence: 99%

The role of TLR4 in pathophysiology of antiphospholipid syndrome‐associated thrombosis and pregnancy morbidity

et al. 2013

View full text Add to dashboard Cite

SummaryThe antiphospholipid syndrome (APS) is an autoimmune disease characterized by the clinical features of recurrent thrombosis in the venous or arterial circulation and fetal losses. Antiphospholipid antibodies (aPL), particularly against the phospholipid binding protein beta-2 glycoprotein I (b2GPI), play an important role in APS pathological mechanisms. aPL can activate intracellular signal transduction in a b2GPI-dependent manner to induce inflammatory responses, and promote hypercoagulable state and recurrent spontaneous abortion when b2GPI is associated with the cell surface receptor. In vivo and in vitro studies show that Annexin A2 (ANXA2) is the high affinity receptor that connects b2GPI to the target cells. However, ANXA2 is not a transmembrane protein and lacks an intracellular signal transduction pathway. Growing evidences suggest that the transmembrane protein toll-like receptor 4 (TLR4) might act as an 'adaptor' for intracellular signal transduction. This review focuses on the role of TLR4 and its signalling pathway in APS pathological mechanisms which will help us better understand the pathological processes of this syndrome.

show abstract

Anti–β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome

Cited by 405 publications

References 54 publications

Prevalence and clinical correlates of anti‐phospholipid antibodies in South Africans with systemic lupus erythematosus

Prevalence and clinical correlates of anti‐phospholipid antibodies in South Africans with systemic lupus erythematosus

The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours?

The role of TLR4 in pathophysiology of antiphospholipid syndrome‐associated thrombosis and pregnancy morbidity

Contact Info

Product

Resources

About